Wall Street Zen upgraded shares of Inventiva (NASDAQ:IVA – Free Report) to a hold rating in a research note released on Saturday morning.
Several other equities research analysts have also weighed in on IVA. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. HC Wainwright increased their target price on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Piper Sandler initiated coverage on Inventiva in a research report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 target price on the stock. Finally, Guggenheim increased their target price on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Inventiva currently has an average rating of “Moderate Buy” and a consensus price target of $16.14.
Get Our Latest Analysis on IVA
Inventiva Price Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,715 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.
About Inventiva
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
- Five stocks we like better than Inventiva
- Expert Stock Trading Psychology Tips
- Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 High-Yield Banks for Investors to Buy on the Dip
- How to Find Undervalued Stocks
- 5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.